This review summarizes the changes in the 5th edition of the WHO Classification of
Endocrine and Neuroendocrine Tumors that relate to the thyroid gland. The new …

Simple Summary Tumor biomarkers are molecules at genetic or protein level, or certain
evaluable characteristics. These help in perfecting patient management. Over the past …

Objective Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with
demonstrated efficacy across various TRK fusion-positive solid tumours. We assessed the …

With increasing attention on the essential roles of the tumour microenvironment in recent
years, the nervous system has emerged as a novel and crucial facilitator of cancer growth. In …

Simple Summary NTRK fusion genes are important but not well studied molecular markers
in thyroid cancer. Their identification could help improve diagnosis and prognosis, and …

The discovery of actionable kinase gene rearrangements has revolutionized the therapeutic
landscape of thyroid carcinomas. Unsolved challenges include histopathologic recognition …

Context Broad genomic analyses among thyroid histologies have been described from
relatively small cohorts. Objective Investigate the molecular findings across a large, real …

The treatment of advanced, radioiodine refractory, differentiated thyroid cancers (RR-DTCs)
has undergone major advancements in the last decade, causing a paradigm shift in the …

Thyroid cancers (TCs) are the most common tumors of the endocrine system and a constant
rise in the number of TC cases has been observed for the past few decades. TCs are one of …

NTRK1/3 rearrangements have been reported in 2.3–3.4% of papillary thyroid carcinoma
(PTC) and are regarded as potential therapeutic targets. Recently, the application of …